Clinical Trials Logo

Advanced Malignancies clinical trials

View clinical trials related to Advanced Malignancies.

Filter by:

NCT ID: NCT04340427 Recruiting - Clinical trials for Advanced Malignancies

A Study of TQB3455 Tablets in Subjects With Advanced Malignancies

Start date: April 10, 2020
Phase: Phase 1
Study type: Interventional

This is a open-label, multicenter, phase I study to evaluate tolerance and pharmacokinetics of TQB3455 tablets in subjects with advanced malignancies.

NCT ID: NCT04085185 Recruiting - Clinical trials for Advanced Malignancies

A Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI110 in Subjects With Advanced Malignant Tumors

Start date: December 4, 2019
Phase: Phase 1
Study type: Interventional

This is an open-label, dose escalation, Phase I study to evaluate the safety, tolerability, pharmacokinetics and efficacy of IBI110 in subjects with advanced malignancies.

NCT ID: NCT03233139 Recruiting - Clinical trials for Advanced Malignancies

Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies

Start date: June 21, 2017
Phase: Phase 1
Study type: Interventional

Part 2 Cohorts A and C This study is being conducted to test the safety and pharmacokinetics of cemiplimab in patients with lung cancer. The study is also being conducted to test if cemiplimab, alone or in combination, can reduce the size of your tumor by helping the immune system destroy the tumor. Part 2 Cohorts D and E This study is being conducted to test the safety and pharmacokinetics of fianlimab and cemiplimab in patients with lung cancer. The study is also being conducted to test if fianlimab and cemiplimab, with or without chemotherapy, can reduce the size of your tumor by helping the immune system destroy the tumor.

NCT ID: NCT02873390 Recruiting - Clinical trials for Advanced Malignancies

PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor

Start date: August 2016
Phase: Phase 1/Phase 2
Study type: Interventional

To evaluate the safety and effectiveness of cell therapy using herinCAR-PD1 cells to treat advanced cancer. Individuals greater than or equal to 18 years of age and less than or equal to 70 years of age who have been diagnosed with relapsed or refractory cancer that has not responded to or has relapsed after standard treatment.

NCT ID: NCT02862561 Recruiting - Chemotherapy Clinical Trials

Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Gastric Cancer

Start date: August 2016
Phase: Phase 1/Phase 2
Study type: Interventional

Objectives: To evaluate the safety and effectiveness of cell therapy using Precision Cell Immunotherapy to treat Advanced Gastric Cancer. Eligibility: Individuals greater than or equal to 18 years of age and less than or equal to 65 years of age who have been diagnosed with Advanced Gastric Cancer.